Altraz
Anastrozole tablets for breast cancer. It blocks the aromatase enzyme, cutting off the oestrogen supply that certain tumours depend on.
- Category
- Oncology Support
- Active ingredient
- Anastrozole
- Route
- Oral use
- Form
- Tablet
- Strengths
- 1mg
Supply requirements for Altraz depend on the medicine and destination. The fulfilment partner must confirm them before accepting an order.
Altraz details
- Condition
- Breast Cancer
- Alternative names
- anastrozole
- Therapeutic class
- Nonsteroidal Aromatase Inhibitor
- Pharmacological class
- Aromatase Inhibitor
- Contraindications
- pregnancy; hypersensitivity to anastrozole
- Minor side effects
- hot flushes; joint pain; headache
- Moderate side effects
- osteoporosis; elevated cholesterol; weakness
- Dosage forms
- Tablet
- Administration route
- Oral use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Alkem Laboratories Ltd
- Onset Time
- 2–4 weeks
- Duration
- 24 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Tamoxifen; Oestrogen-containing products
- Age restrictions
- Approved for postmenopausal females.
Serious side effects
anaphylaxis, requires immediate medical attention; ischaemic cardiovascular events, requires immediate medical attention
Patient summary
Anastrozole tablets for breast cancer. It blocks the aromatase enzyme, cutting off the oestrogen supply that certain tumours depend on.
Mechanism of action
Inhibits the aromatase enzyme, which blocks peripheral oestrogen synthesis in postmenopausal women to limit tumour fuel.
Pregnancy and breastfeeding
Pregnancy: Strictly contraindicated. Can cause fetal mortality. Breastfeeding: Avoid.